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1. Introduction {#sec0005}
===============

Bone is the commonest site of metastatic spread in prostate cancer [@bib0005], and traditionally, bone metastases have been evaluated conventionally using ^99m^Tc methylene diphosphonate (^99m^Tc-MDP) bone scintigraphs to assess the presence and extent of metastases. The extent or burden of skeletal involvement based on ^99m^Tc-MDP bone scans has been reported to be prognostic in prostate cancer [@bib0010]. Recently, the individual and combined analyses of two phase III randomised controlled trials have reported that the extent of bone metastases is predictive for selecting newly diagnosed metastatic prostate cancer patients and men with lower metastatic burden benefit from prostate radiotherapy (RT) [@bib0015], [@bib0020], [@bib0025]. Based on the results of these two trials, prostate RT is now considered an option for patients with low metastatic burden [@bib0030], [@bib0035], [@bib0040].

Counting bone metastases to ascertain metastatic burden is limited by interobserver variation and it is not quantitative, failing to account for lesional volume or coalescence [@bib0045], [@bib0050]. Therefore, a standardised quantitative imaging biomarker would be a better method for the quantification of metastatic disease burden in bone. Previous reports have shown the artificial neural network--based automated bone scan index (aBSI) to be accurate and reproducible in this regard [@bib0055], [@bib0060], providing a quantitative assessment of bone metastasis burden as a fraction of skeletal weight. In prospective evaluation in a phase 3 clinical trial, it was an independent prognostic factor in metastatic castration-resistant prostate cancer [@bib0065]. Herein, we sought to determine its utility as a predictive imaging biomarker for defining a population of men newly diagnosed with metastatic prostate cancer who might benefit from the addition of prostate RT to standard of care (SOC) systemic therapies.

2. Patients and methods {#sec0010}
=======================

2.1. Trial design and conduct {#sec0015}
-----------------------------

STAMPEDE is a multiarm, multistage trial that enrols men with advanced high-risk or metastatic prostate cancer. The trial is registered as NCT 00268476 and ISRCTN 78818544, and has the relevant regulatory, national ethics, and local practical site approval. All patients provided written informed consent.

Herein, we focus on patients who were randomised within STAMPEDE "M1\|RT comparison", that is, SOC (arm A) or SOC and prostate RT (arm H) [@bib0020]. Briefly, patients with newly diagnosed metastatic prostate cancer, with no previous radical treatment and no contraindication to RT, were eligible for this comparison. There were no age restrictions; patients had to be fit for chemotherapy and have no significant cardiovascular history. Patients underwent baseline imaging prior to randomisation as per study protocol, which included computed tomography or magnetic resonance imaging (MRI) of the pelvis and abdomen; bone scan or equivalent, for example, whole-body MRI; and chest x-ray if chest was not included in the computed tomography or MRI. Randomisation was stratified according to centre, age at randomisation (\<70 vs ≥70 yr), World Health Organization (WHO) performance status (0 vs 1 or 2), nodal involvement (N0 vs N1 vs NX), type of androgen deprivation therapy (ADT), and use of aspirin or nonsteroidal anti-inflammatory drugs. Planned docetaxel use was added as a stratification factor on 17 December 2015. Randomisation was in a 1:1 ratio to receive SOC systemic therapy alone or SOC plus prostate RT. The SOC was lifelong ADT, with up-front docetaxel permitted from 17 December 2015. Docetaxel was given as six 3-weekly cycles of 75 mg/m², with or without prednisolone 10 mg daily. Men allocated RT received either a daily (55 Gy in 20 fractions over 4 wk) or a weekly (36 Gy in six fractions over 6 wk) schedule that was nominated before randomisation. Full details are provided in the study protocol, which can be found at <http://www.stampedetrial.org>.

2.2. Image analysis {#sec0020}
-------------------

The aBSI was calculated blinded to treatment assignment and outcome data using the Exini aBSI v3.2.1 software (EXINI Diagnostics, Lund, Sweden). Anterior and posterior Digital Imaging and Communications in Medicine (DICOM) images of baseline planar whole-body bone scans, which met the image and the pixel compression requirements (Supplementary methods), were evaluated retrospectively to calculate aBSI as described previously [@bib0065], [@bib0070]. Briefly, the skeleton is segmented into 12 regions; hotspots are detected and classified as metastatic or benign by an artificial neural network. Each metastatic hotspot size is divided by the size of the corresponding skeletal region and multiplied by a weight fraction constant. The aBSI is then calculated as the sum of all such hotspots. No manual correction to hotspot classification was applied unless it represented a large urinary bladder, a urinary catheter, or tracer contamination.

2.3. Outcomes {#sec0025}
-------------

We used the trial's primary and intermediate outcome measures---overall (OS) and failure-free (FFS) survival, respectively. OS was defined as the time from randomisation to death from any cause and FFS as the time from randomisation to the first of the following events: biochemical failure, progression either locally in lymph nodes or in distant metastases, or death from prostate cancer [@bib0020]. Biochemical failure was defined as a rise in PSA above its lowest reported level within 24 wk after enrolment of 50% and to at least 4 ng/mL; patients without a fall of 50% were considered to have biochemical failure at time zero. Secondary outcome measures, progression-free survival (defined as FFS but without biochemical events), metastatic progression-free survival (defined as the time from randomisation to new metastases or progression of existing metastases or death), prostate cancer--specific survival, and symptomatic local event--free survival (defined as any of the following: urinary tract infection, new urinary catheterisation, acute kidney injury, transurethral resection of the prostate, urinary tract obstruction, ureteric stent, nephrostomy, colostomy, and surgery for bowel obstruction) were also evaluated. Patients without the event of interest were censored at the time they were last known to be event free. The outcome dataset, frozen for the published STAMPEDE "M1\|RT comparison", was used for survival analyses [@bib0020].

2.4. Statistical analyses {#sec0030}
-------------------------

To evaluate whether the effect of treatment varied by aBSI (treatment-aBSI interaction), a multivariable fractional polynomial interaction (MFPI) test using a nested Cox regression model was performed. This was to improve the statistical power for detecting interaction of a continuous variable with treatment [@bib0075] and to avoid arbitrary categorisation [@bib0080]. For the MFPI analyses, aBSI was modelled as a continuous variable using a second-degree fractional polynomial functional form separately for each treatment group using the same powers. The *p* value from a likelihood ratio test of treatment-aBSI interaction is presented. The MFPI model-estimated treatment effect as a function of aBSI was plotted graphically as hazard ratio (HR) and 95% confidence interval (CI). Further technical details regarding the MFPI have been published previously [@bib0085], [@bib0090].

The effect of treatment relative to aBSI was also assessed graphically using the subpopulation treatment effect pattern plot (STEPP) [@bib0095]. The tail-oriented version of STEPP was used, in which 2*g* -- 1 overlapping subpopulations are created based on a parameter *g*. Within each subpopulation, relative treatment effects were evaluated using Cox regression. Further details on how subpopulations are created have been described previously [@bib0095]. Graphical assessment was based on the evaluation of estimated treatment effect in relation to aBSI: aBSI-treatment interaction would be manifested as a nonhorizontal line, that is, estimated treatment effect varying by aBSI, whereas a line parallel to the *X*-axis would indicate a constant treatment effect across the range of aBSI values.

We conducted further analysis by dividing the cohort into four quartiles (Q1--Q4) based on aBSI, with Q1 being the lowest and Q4 being the highest aBSI quartile. Within each subgroup defined by an aBSI quartile, treatment effects were evaluated using Kaplan-Meier (KM) plots and estimated using adjusted Cox regression. Cox models were adjusted for minimisation factors used at randomisation: age (\<70 or ≥70 yr), N stage (N0, N+, or NX), WHO performance status (0 or 1--2), use of nonsteroidal anti-inflammatory drugs or aspirin (uses either or none of these), planned use of docetaxel (yes or no); except for hospital and planned ADT. An HR of \<1 favours prostate RT + SOC. Median follow-up was calculated by reverse censoring on death. All statistical analyses were performed using Stata v15.1 (StataCorp, College Station, TX, USA).

3. Results {#sec0035}
==========

Baseline bone scans from 660 of the 2061 men with newly diagnosed metastatic prostate cancer, randomised between 22 January 2013 and 2 September 2016 within the STAMPEDE "M1\|RT comparison", had digital scan-based information usable for aBSI calculation and were included in this study ([Fig. 1](#fig0005){ref-type="fig"}). Baseline characteristics of these patients were balanced between SOC and SOC + RT groups ([Table 1](#tbl0005){ref-type="table"}) and were broadly similar to the M1\|RT comparison (Supplementary Table 1). Median age at randomisation was 68 yr, and median PSA before ADT was 100 ng/mL. The median aBSI was 0.9 (interquartile range \[IQR\] 0.1--4.1) and was balanced between the treatment groups (*p* =  0.59, Wilcoxon rank-sum test). Median follow-up of the study cohort was 39 mo (IQR 24--48).Fig. 1Flow diagram showing selection of patients. aBSI = automated bone scan index; DICOM = Digital Imaging and Communications in Medicine; RT = radiotherapy.Fig. 1Table 1Baseline characteristics of patients included in the aBSI cohort.Table 1SOC (*n* = 323)SOC + RT (*n* = 337)*n*%*n*%Age at randomisationMedian6868IQR63--7363--73PSA (ng/mL) before ADTMedian94111IQR33--35536--331WHO performance status024877252751--275238525Primary tumour stage≤T235113210T31956020561T472228325TX217175Gleason score≤7501564198--102608126178Unknown134124Regional node statusN0932911133N12076421163NX237154Nominated RT schedule36 Gy in 6 f over 6 wk158491795355 Gy in 20 f over 4 wk1655115847Planned docetaxelNo2618127682Yes62196118Metastatic sitesBone2898930691NRLN94299528Lung10393Liver5231Other11382Metastatic burden[a](#tblfn0005){ref-type="table-fn"}Low1354214944High1885818856Number of bone metastases≤314043145434--649155215≥71344214042aBSIMedian10.8IQR0.2--4.20.1--3.8[^1][^2]

Using the MFPI procedure, there was evidence of aBSI-treatment interaction for OS (*p* =  0.04, MFPI procedure). Graphical assessment of estimated treatment effect against aBSI suggests that only patients with a low aBSI receive survival benefit associated with prostate RT (HR and 95% CI below 1; Supplementary Fig. 1A). Examination of estimated treatment effect in STEPP plots also showed a sloping nonhorizontal line for treatment effect, demonstrating that the treatment effect varies with aBSI and approximately reflects the estimated pattern of interaction (Supplementary Fig. 2A). Similarly, for FFS we found good evidence of aBSI-treatment interaction (*p* \<  0.01, MFPI procedure). A plot of estimated treatment effect from MFPI analysis indicates that FFS benefit was greatest for patients with a low aBSI, with the upper 95% CI crossing the line of equivalence (HR: 1) just below 1 aBSI (Supplementary Fig. 1B). A similar pattern of changing treatment effect can be seen in the corresponding STEPP graph (Supplementary Fig. 2B).

Further analysis was conducted in quartiles based on aBSI value, and aBSI was found to be balanced between the treatment groups within each aBSI quartile (Supplementary Tables 2--6). In quartile 1 comprising patients with aBSI \<0.2, there was good evidence of survival benefit associated with the addition of prostate RT to SOC over SOC alone (HR = 0.50, 95%CI 0.28--0.91; 3-yr KM-estimated survival 76% with SOC vs 83% with SOC + RT; [Table 2](#tbl0010){ref-type="table"} and [Fig. 2](#fig0010){ref-type="fig"}A). No evidence of survival benefit was noted with prostate RT in the other aBSI quartiles (HRs of 1.06 \[95% CI 0.54--2.08\], 1.00 \[95% CI 0.60--1.64\], and 1.10 \[95% CI 0.72--1.69\] in quartiles 2, 3, and 4 respectively; [Table 2](#tbl0010){ref-type="table"} and [Fig. 2](#fig0010){ref-type="fig"}B--D).Table 2Summary of relative treatment effects in aBSI quartiles for overall and failure-free survival.Table 2No. of events/no. of patientsHazard ratio (95% CI)[a](#tblfn0010){ref-type="table-fn"}SOCSOC + RTOverall survival aBSI quartile 129/7919/890.50 (0.28--0.91) aBSI quartile 217/7823/881.06 (0.54--2.08) aBSI quartile 332/8432/781.00 (0.60--1.64) aBSI quartile 445/8246/821.10 (0.72--1.69)Failure-free survival aBSI quartile 154/7936/890.35 (0.22--0.54) aBSI quartile 255/7850/880.67 (0.44--1.00) aBSI quartile 366/8460/780.81 (0.56--1.16) aBSI quartile 470/8273/821.08 (0.76--1.52)[^3][^4]Fig. 2Kaplan-Meier plots for overall survival by treatment in (A--D) aBSI quartiles 1--4. aBSI = automated bone scan index; RT = radiotherapy; SOC = standard of care.Fig. 2

For FFS, we observed strong evidence of improved FFS with the use of prostate RT in quartile 1 with the lowest aBSI range. This becomes weaker in quartiles 2 and 3, and disappears in quartile 4 with the highest aBSI values. The estimated HR of adding prostate RT to SOC on FFS was 0.35 (95% CI 0.22--0.54; 3-yr KM-estimated FFS 26% with SOC vs 61% with SOC + RT; [Table 2](#tbl0010){ref-type="table"} and [Fig. 3](#fig0015){ref-type="fig"}A). In quartiles 2, 3, and 4, the estimated HRs for the effect of prostate RT in comparison with SOC on FFS are 0.67 (95% CI 0.44--1.00), 0.81 (95% CI 0.56--1.16), and 1.08 (95% CI 0.76--1.52), respectively ([Table 2](#tbl0010){ref-type="table"} and [Fig. 3](#fig0015){ref-type="fig"}B--D).Fig. 3Kaplan-Meier plots for failure-free survival by treatment in (A--D) aBSI quartiles 1--4. aBSI = automated bone scan index; RT = radiotherapy; SOC = standard of care.Fig. 3

We evaluated the impact of prostate RT on secondary efficacy measures within aBSI quartiles. In aBSI quartile 1, there was evidence of benefit from adding prostate RT to progression-free survival (HR = 0.43, 95% CI 0.26--0.71), metastatic progression-free survival (HR = 0.50, 95% CI 0.30--0.85), prostate cancer--specific survival (sub-distribution HR = 0.37, 95% CI 0.17--0.81), and symptomatic local event-free survival (HR = 0.53, 95% CI 0.31--0.90). There was no evidence of benefit from the addition of prostate RT in aBSI quartiles 2--4 on any secondary outcome measures (Supplementary Table 7).

4. Discussion {#sec0040}
=============

In this study, we found that a low baseline aBSI in patients with newly diagnosed metastatic prostate cancer is *predictive* of survival benefit when prostate RT is added to SOC systemic therapy. The clinical implication of this study is that the widely available conventional bone scan can be evaluated using an observer-independent automated technique to select patients who would benefit from prostate RT as part of multimodality treatment.

Two trials have previously reported a beneficial effect of prostate RT in patients with low metastatic burden based on manual bone metastasis counts. The HORRAD trial that enrolled 432 patients showed, in a subgroup of 160 patients with fewer than five bone metastases, some evidence of OS benefit of the combination of prostate RT and ADT compared with ADT alone (HR = 0.68, 95% CI 0.42--1.10) [@bib0015]. However, this subgroup analysis was underpowered and the categorisation was done in groups based on bone metastases count as 1--4, 5--15, and \>15. In the STAMPEDE "M1\|RT" comparison, a prespecified, well-powered, and directionally hypothesised subgroup analysis based on the CHAARTED definition showed significant improvement in survival associated with the addition of prostate RT to SOC in patients with low metastatic burden (HR = 0.68, 95% CI 0.52--0.90) [@bib0020]. Further exploratory analysis of 1939 patients within the STAMPEDE M1\|RT comparison has shown that manual bone metastasis counts are *predictive* of OS and FFS benefit, and this benefit is limited to patients with only non-regional lymph node metastasis (M1a) or three or fewer bone metastases regardless of axial or appendicular location without any visceral or other metastasis [@bib0100]. Given that aBSI is highly correlated with manual bone counts, the current findings based on aBSI are supported by previous large-scale studies based on manual counting.

This study also highlights that beyond counting the number of bone metastases, metastatic disease volume is another characteristic with potential to be clinically useful in selecting M1 patients for prostate RT. In this study, aBSI quartile 1 (aBSI \<0.2) consisted predominantly of patients with three or fewer bone metastases (93%). However, these represented 55% of the men with three or fewer bone metastases; the other 45% belonged to aBSI quartiles 2 (37%) and 3 (8%) with higher aBSI. This suggests that although certain patients might meet the enumeration criteria, they might not meet the "aBSI volume" threshold. Most patients in this study had bone metastases, but a proportion also had bone, node, and visceral metastases alone or in combination. Quantification of nonosseous metastases is not addressed using the aBSI methodology, and the implications of this need to be studied further. Previous exploratory analysis of the STAMPEDE "M1\|RT comparison" has demonstrated that patients with a negative bone scan and only nonregional lymph node metastases (M1a) benefit from prostate RT, while patients with any visceral metastasis (M1c) do not [@bib0100]. An exploratory analysis that accounts for site and volume of lymph node, bone, and visceral metastases is currently on-going within STAMPEDE. In parallel, imaging methodology in prostate cancer is developing rapidly, with newer techniques, such as prostate-specific membrane antigen positron emission tomography, whole-body MRI, and others, gaining popularity. Given the higher accuracy of novel imaging than conventional imaging, we would expect newer methodologies to detect more metastases [@bib0105]. However, the true relevance of these findings based on newer imaging in relation to outcomes from treatment is unknown. These newer imaging methods will need further detailed study to ascertain their true individual clinical relevance. Future studies can evaluate the prognostic and predictive relevance of quantitative imaging biomarkers.

Our study has limitations given its exploratory and retrospective nature. However, even after the exclusion of a number of patients whose bone scans could not be evaluated for aBSI because of a lack of uncompressed DICOM pixel data or only spot images, 660 fully categorised patients were available for the study. Baseline characteristics and follow-up survival data of the aBSI cohort and total trial population were determined to be similar. The use of the MFPI procedure allowed the use of all the available information from the continuous aBSI variable, and the results did not depend on any cut-point for an interaction test. Previous simulation studies have shown that the power of the MFPI procedure to identify an interaction is greater than the power of the common approach based on dichotomisation using cut-points [@bib0110], [@bib0115].

The aBSI method to evaluate bone metastatic burden has several advantages that are potentially useful for the patient and clinician. It has previously undergone analytical validation demonstrating rapid (\<10 s per scan), accurate, and reproducible assessments of metastatic burden, minimising interobserver variability [@bib0055], [@bib0060]. Given the widespread availability of conventional bone scan and its use in randomised controlled trials, the quantitative aBSI method can potentially be used prospectively for stratifying patients in clinical trials evaluating local treatment for newly diagnosed metastatic prostate cancer. It can also be used to monitor treatment responses [@bib0120]. This can be done easily using technology that is available widely and by prospective implementation of standardised operating procedures to acquire, store, and analyse bone scan DICOM images by clinical teams undertaking the patient evaluation and treatment. A number of on-going trials are evaluating local and metastasis-directed treatments in metastatic prostate cancer [@bib0125]. These trials can further evaluate aBSI as a standardised method of metastatic burden quantification.

5. Conclusions {#sec0045}
==============

A low aBSI is predictive of survival benefit associated with the addition of prostate RT to SOC systemic therapies. This methodology has significant potential for use in the selection of newly diagnosed metastatic prostate cancer patients who might benefit from RT to the primary lesion.
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[^1]: aBSI = automated bone scan index; ADT = androgen deprivation therapy; f = fractions; IQR = interquartile range; NRLN = nonregional lymph node; PSA = prostate-specific antigen; RT = radiotherapy; SOC = standard of care; WHO = World Health Organization.

[^2]: CHAARTED definition.

[^3]: aBSI = automated bone scan index; CI = confidence interval; NSAID = nonsteroidal anti-inflammatory drug; RT = radiotherapy; SOC = standard of care; WHO PS = World Health Organization performance status.

[^4]: Adjusted for age (\<70 or ≥70 yr), N stage (N0, N+, or NX), WHO PS (0 or 1--2), NSAID or aspirin use (uses either or none of these), and planned docetaxel use (yes or no).
